Interviews
If approved, VER-01 would be the first cannabinoid-based therapy for chronic low back pain.
After AI’s magic wand status, it's now come to Google and Open AI CEOs talking of the likelihood of a bubble burst. In this interview, Parexel’s India head discusses how to view returns on such investments, the CRO’s own use cases and the US FDA’s keenness on transparency and open dialogue.
The CEOs of two early-stage biotechs explain to Scrip why investor interest in ocular gene therapies is surging and how they aim to attract big pharma partners.
Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’
Five-year Agamree data shows the novel steroid is a safer and equally effective treatment to standard of care deflazacort or prednisone, the Swiss biotech argues.
Medicxi V marks the venture capital firm's biggest fund till date, raising its tally to six funds in the last decade, totaling over €2bn.
New CEO, Eran Ophir, is banking on positive readouts from AstraZeneca and Arcus’s TIGIT programs soon validating its science as it pushes ahead with its immuno-oncology pipeline in a field littered with disappointments.
The Swiss major plans to submit the positive results from the NEPTUNUS program to health authorities globally in early 2026.
Boehringer’s PDE4B inhibitor Jascayd was approved for IPF in China on Oct. 22, marking its second nod globally soon after the US. The German firm discusses with Scrip the opportunities and challenges in this market.
KIMCo CEO talks to Scrip about how the Korean open innovation platform and life science accelerator and its member firms are notching up efforts to nurture Korean bioventures through the country’s first coalition fund.
Positive data from the PSMAddition trial potentially doubles the number of prostate cancer patients eligible for treatment with the Swiss major’s big-selling radioligand therapy but a discussant at ESMO was not convinced by the study.
Data from the EV-303/KEYNOTE-905 trial show the potential for the combination of Astellas/Pfizer’s ADC and Merck’s PD1 blocker to redefine standard of care.
Listen now as Citeline speaks with Anil Okay, CEO of Europe’s fast-growing pharma B2B, Adalvo. Learn what the company’s recent acquisition by private equity firm EQT means for both Adalvo and for the industry at large, and find out what trends will be fueling pharma in the years ahead.
The vocal shareholder tells Scrip that other investors have reached out supporting its push for a sale of the vaccine maker.
Chief medical officer Eliav Barr and EyeBio chief scientific officer Tony Adamis talk to Scrip about progress in eye diseases post Merck’s EyeBio acquisition.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
Yuhan's R&D president talks to Scrip about the leading Korean pharma firm’s open innovation strategy with Korean bioventures, as well as other strategies crucial for the company to transform into a major global player.
In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.